The price of Gilead Sciences, Inc. (NASDAQ: GILD) closed at $73.98 in the last session, up 0.78% from day before closing price of $73.41. In other words, the price has increased by $+0.57 from its previous closing price. On the day, 7062246 shares were traded. GILD stock price reached its highest trading level at $73.98 during the session, while it also had its lowest trading level at $72.80.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at GILD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.04 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.42. For the most recent quarter (mrq), Quick Ratio is recorded 1.27 and its Current Ratio is at 1.43. In the meantime, Its Debt-to-Equity ratio is 1.12 whereas as Long-Term Debt/Eq ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on February 22, 2024, Downgraded its rating to Hold and sets its target price to $82 from $91 previously.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $75.
BofA Securities Upgraded its Neutral to Buy on September 08, 2023, whereas the target price for the stock was revised from $88 to $95.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 29 ’24 when Parsey Merdad sold 8,230 shares for $72.74 per share. The transaction valued at 598,624 led to the insider holds 92,706 shares of the business.
Parsey Merdad sold 2,000 shares of GILD for $146,360 on Feb 28 ’24. The Chief Medical Officer now owns 100,936 shares after completing the transaction at $73.18 per share. On Feb 12 ’24, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 910,000 shares for $22.00 each. As a result, the insider paid 20,020,000 and bolstered with 4,126,119 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 92.16B and an Enterprise Value of 109.89B. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.43, and their Forward P/E ratio for the next fiscal year is 9.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.21. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.41 while its Price-to-Book (P/B) ratio in mrq is 4.04. Its current Enterprise Value per Revenue stands at 4.05 whereas that against EBITDA is 10.47.
Stock Price History:
The Beta on a monthly basis for GILD is 0.20, which has changed by -6.07% over the last 52 weeks, in comparison to a change of 32.31% over the same period for the S&P500. Over the past 52 weeks, GILD has reached a high of $87.86, while it has fallen to a 52-week low of $71.37. The 50-Day Moving Average of the stock is 76.70, while the 200-Day Moving Average is calculated to be 77.37.
Shares Statistics:
According to the various share statistics, GILD traded on average about 7.26M shares per day over the past 3-months and 8.52M shares per day over the past 10 days. A total of 1.25B shares are outstanding, with a floating share count of 1.24B. Insiders hold about 0.10% of the company’s shares, while institutions hold 87.15% stake in the company. Shares short for GILD as of Feb 29, 2024 were 19.67M with a Short Ratio of 2.71, compared to 15.66M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.58% and a Short% of Float of 1.77%.
Dividends & Splits
The forward annual dividend rate for GILD is 3.02, which was 3.00 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 4.09%, it implies a Forward Annual Dividend Yield of 4.16%. The stock’s 5-year Average Dividend Yield is 3.97. The current Payout Ratio is 66.62% for GILD, which recently paid a dividend on Mar 28, 2024 with an ex-dividend date of Mar 14, 2024. Stock splits for the company last occurred on Jan 28, 2013 when the company split stock in a 2:1 ratio.
Earnings Estimates
The company has 20 analysts who recommend its stock at the moment. On average, analysts expect EPS of $1.58 for the current quarter, with a high estimate of $1.97 and a low estimate of $1.21, while EPS last year was $1.37. The consensus estimate for the next quarter is $1.71, with high estimates of $2.05 and low estimates of $1.44.
Analysts are recommending an EPS of between $8 and $6.85 for the fiscal current year, implying an average EPS of $7.09. EPS for the following year is $7.43, with 28 analysts recommending between $8.25 and $6.61.
Revenue Estimates
According to 20 analysts, the current quarter’s revenue is expected to be $6.37B. It ranges from a high estimate of $6.78B to a low estimate of $5.96B. As of the current estimate, Gilead Sciences, Inc.’s year-ago sales were $6.35B, an estimated increase of 0.20% from the year-ago figure. For the next quarter, 19 analysts are estimating revenue of $6.78B, an increase of 2.70% over than the figure of $0.20% in the same quarter last year. There is a high estimate of $6.99B for the next quarter, whereas the lowest estimate is $6.56B.
A total of 29 analysts have provided revenue estimates for GILD’s current fiscal year. The highest revenue estimate was $28.03B, while the lowest revenue estimate was $27.09B, resulting in an average revenue estimate of $27.5B. In the same quarter a year ago, actual revenue was $27.12B, up 1.40% from the average estimate. Based on 29 analysts’ estimates, the company’s revenue will be $28.04B in the next fiscal year. The high estimate is $29.21B and the low estimate is $27.24B. The average revenue growth estimate for next year is up 2.00% from the average revenue estimate for this year.
